Ischemic heart disease, factor predisposing to Barrett’s adenocarcinoma: A case control study

Table 1 Clinical effects of aspirin in high risk population (clinical trials) n (%)

Characteristics	Patients in the analysis	Patients excluded from the analysis	P
Patients with esophageal adenocarcinoma
n	83	120
Age [mean (SD)], yr	73 (SD = 11.3)	73 (SD = 11.5)	1.00
Male gender	73 (61)	58 (70)	0.19
Current smokers	44 (37)	33 (40)	0.66
Cig. Cons. (in PY) [mean (SD)]	22.5 (SD = 30.2)	22.1 (SD = 27.3)	0.92
Alcohol abusers	32 (27)	21 (25)	0.96
BMI ≥ 25	57 (48)	40 (47)	0.96
Presence of hiatus hernia	73 (61)	52 (63)	0.91
Ischemic heart disease	40 (33)	27 (33)	0.97
Use of aspirin	17 (14)	12 (14)	0.88
Low socioeconomic status	26 (22)	18 (22)	0.87
Dur of reflux [in Y-mean (SD)]	28.5 (SD = 10.1)	27.8 (SD = 12.2)	0.66
Freq of refl (d/wk) [mean (SD)]	5.4 (SD = 2.4)	5.4 (SD = 2.6)	1.00
Patients with Barrett’s esophagus
n	426	521
Age [mean (SD)], yr	68 (SD = 14)	68 (SD = 13)	1.00
Male gender	264 (62)	316 (61)	0.73
Current smokers	136 (32)	174 (33)	0.68
Cig. Cons. (in PY) [mean (SD)]	19.8 (SD = 28.4)	20.3 (SD = 29.4)	0.79
Alcohol abusers	108 (25)	130 (25)	0.95
BMI ≥ 25	232 (54)	283 (54)	0.98
Barrett’s length (in cm)	6.6 (SD = 3.9)	6.6 (SD = 3.7)	1.00
Presence of hiatus hernia	304 (71)	371 (71)	0.98
Ischemic heart disease	83 (19)	99 (19)	0.92
Use of aspirin	87 (20)	109 (21)	0.91
Low socioeconomic status	69 (16)	83 (16)	0.98
Dur of reflux [in Y-mean (SD)]	16.1 (SD = 9.9)	16.4 (SD = 10.2)	0.65
Freq of refl (d/wk) [mean (SD)]	5.1 (SD = 2.3)	5.1 (SD = 2.5)	1.00

Cig. Cons.: Cigarette consumption in total throughout life; PY: Pack-years; BMI: Body mass index; Dur of reflux: Duration of reflux; Freq of refl (d/wk): Frequency of reflux episodes in days/week.